NCT01577004 · COMPLETED
Do Apolipoprotein E Polymorphisms Influence Risk of Cognitive Decline by Modulating Omega-3 Fatty Acid Metabolism?
This study tests whether a daily fish oil supplement (EPA and DHA, two omega-3 fats) changes how the body handles omega-3s, and whether it affects thinking and memory test scores. Researchers track a labeled form of DHA in the blood. It is not a drug phase trial, so it is early research, not proof of benefit.
You may qualify if
- MCI will be defined by Winblad et al. (33), with diagnosis confirmed by a geriatrician through neuropsychological evaluation done within the last 6 months.
- if diagnosis was done more than 6 months ago, the subject will be re-evaluated before inclusion to confirm MCI rather than conversion to AD.
You're excluded if
- tobacco
- malnutrition (assessed from blood albumin, haemoglobin and lipids)
- subjects already taking an EPA+DHA supplements
- swallowing problems, uncontrolled diabetes (raised fasting glucose, haemoglobin A1c)
- uncontrolled thyroid disease
- severe renal failure
- chronic immune condition or inflammation (raised C-reactive protein, white cell count)
- cancer
- recent major surgery or cardiac event
- uncorrected visual or hearing problems
- dementia
- ongoing or past severe drug or alcohol abuse
- psychiatric difficulties or depression as evaluated by the geriatric depression scale test (34)
- use of psychotropic medications except for short-acting benzodiazepines taken before sleep.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2012-04-13